A big congratulations to the Convatec team on the regulatory approval of ConvaNiox – a major milestone for nitric oxide-based wound care.

30 Technology is excited to announce that on October 16, 2024, the first patient was enrolled into the NOPA study.

30 Technology is pleased to announce the successful completion of the interim analysis for Stage 1 of the Phase 2 trial evaluating RESP301 in the treatment of tuberculosis (RESP30X-EBA).